| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2018 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ROYALTY PHARMA PLC | 3 | Q2 2024 | 13.3% |
| ROIVANT SCIENCES LTD | 3 | Q2 2024 | 8.3% |
| KEROS THERAPEUTICS INC | 3 | Q2 2024 | 9.8% |
| PROTAGONIST THERAPEUTICS INC | 3 | Q2 2024 | 10.5% |
| CYTOKINETICS INC | 3 | Q2 2024 | 8.7% |
| BRIDGEBIO PHARMA INC | 3 | Q2 2024 | 6.0% |
| ALNYLAM PHARMACEUTICALS INC | 3 | Q2 2024 | 6.1% |
| ARBUTUS BIOPHARMA CORP | 3 | Q2 2024 | 3.1% |
| ASCENDIS PHARMA A/S | 3 | Q2 2024 | 2.1% |
| IMMUNOVANT INC | 3 | Q2 2024 | 2.4% |
View ADAR1 Capital Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-13 |
| 4 | 2024-08-12 |
| SC 13G | 2024-08-01 |
| 3 | 2024-07-31 |
| 3/A | 2024-07-11 |
| SC 13G | 2024-07-10 |
| 3 | 2024-07-09 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
View ADAR1 Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.